Login to Your Account

Medivir, Roche In $42M Pact For Preclinical HIV Compound

By Cormac Sheridan

Wednesday, April 17, 2002
Swedish biotechnology firm Medivir AB unveiled Monday its biggest drug development deal to date a licensing agreement worth up to US$42 million with F. Hoffmann-La Roche Ltd. for Medivir’s candidate HIV treatment, MV026048. (BioWorld International)

To continue reading subscribe now to BioWorld Asia (formerly International)

Learn More about BioWorld Asia (formerly International)

Already a subscriber? Sign In or Buy now to activate your subscription